The group's principal activity is to develop patented polymer- based delivery systems that enhance the safety and effectiveness of pharmaceutical compounds. These delivery systems are targeted at pain management, inflammation, oncology and ophthalmology applications. The group is in process of the development of bioerodible injectable and implantable systems under the trade names biochronomer(tm) and bioerodimer(tm). The projects are under feasibility study and will require marketing clearance from the fda before they can be sold in the United States. The group has already developed and commercialized ethical dermatological products by the name retin-a micro and carac.
